Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SGMT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Devesh Gandhi | 3.75M | 6.1% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | SilverArc Capital Management, LLC | 3.75M | 6.1% | SCHEDULE 13G ↗ |
| Oct 7, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Michael Kramarz | 5.51M | 7.6% | SCHEDULE 13G ↗ |
| Oct 7, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Robert Egen Atkinson | 5.51M | 7.6% | SCHEDULE 13G ↗ |
| Oct 7, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Commodore Capital Master LP | 5.51M | 7.6% | SCHEDULE 13G ↗ |
| Oct 7, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Commodore Capital LP | 5.51M | 7.6% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Dmitry Balyasny | 3.63M | 5.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Dames GP LLC | 3.63M | 5.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Balyasny Asset Management Holdings LP | 3.63M | 5.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Bam GP LLC | 3.63M | 5.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Balyasny Asset Management L.P. | 3.63M | 5.9% | SCHEDULE 13G ↗ |
| Jul 30, 2026 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | BlackRock, Inc. | 4.75M | 7.8% | SCHEDULE 13G ↗ |
| Dec 18, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | KPCB PBD Associates, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Dec 18, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | KPCB Pandemic and Bio Defense Fund, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Woodline Partners LP | 1.50M | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Steven A. Cohen | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Point72 Capital Advisors, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Point72 Asset Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Woodline Partners LP | 2.55M | 8.3% | SCHEDULE 13G ↗ |
| Jun 24, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Ascletis Pharma Inc. | 1.50M | 4.9% | SCHEDULE 13G/A ↗ |
| Jun 24, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | AP11 Limited | 1.50M | 4.9% | SCHEDULE 13G/A ↗ |
| May 20, 2025 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | Ascletis Pharma Inc. | 1.65M | 5.4% | SCHEDULE 13G ↗ |
| May 20, 2025 | SCHEDULE 13G | SGMT Sagimet Biosciences Inc. | AP11 Limited | 1.65M | 5.4% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Steven A. Cohen | 1.76M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Point72 Capital Advisors, Inc. | 1.76M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Point72 Asset Management, L.P. | 1.76M | 5.7% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Scott D. Sandell | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Mohamad H. Makhzoumi | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Patrick J. Kerins | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Anthony A. Florence, Jr. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Forest Baskett | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Nea 13 GP, Ltd | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | NEA Partners 13, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 13, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | New Enterprise Associates 13, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | SGMT Sagimet Biosciences Inc. | Blue Owl Capital Holdings LP | 1.32M | 4.3% | SCHEDULE 13G/A ↗ |
35 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 11:25 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances